Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim

Last Updated: October 15, 2019

DrugPatentWatch Database Preview

Invagen Pharms Company Profile

See Plans and Pricing

« Back to Dashboard

What is the competitive landscape for INVAGEN PHARMS, and what generic and branded alternatives to INVAGEN PHARMS drugs are available?

INVAGEN PHARMS has fifty-four approved drugs.

There are two tentative approvals on INVAGEN PHARMS drugs.

Summary for Invagen Pharms
US Patents:0

Drugs and US Patents for Invagen Pharms

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Invagen Pharms LISINOPRIL AND HYDROCHLOROTHIAZIDE hydrochlorothiazide; lisinopril TABLET;ORAL 204058-001 May 23, 2017 AB RX No No   See Pricing   See Pricing
Invagen Pharms BUPROPION HYDROCHLORIDE bupropion hydrochloride TABLET, EXTENDED RELEASE;ORAL 206556-001 Aug 26, 2016 AB3 RX No No   See Pricing   See Pricing
Invagen Pharms CYCLOBENZAPRINE HYDROCHLORIDE cyclobenzaprine hydrochloride TABLET;ORAL 090478-002 Jul 23, 2010 AB RX No No   See Pricing   See Pricing
Invagen Pharms QUINAPRIL HYDROCHLORIDE quinapril hydrochloride TABLET;ORAL 078457-001 Aug 24, 2007 AB RX No No   See Pricing   See Pricing
Invagen Pharms FENOFIBRATE (MICRONIZED) fenofibrate CAPSULE;ORAL 207378-002 Mar 28, 2017 AB RX No No   See Pricing   See Pricing
Invagen Pharms AMLODIPINE BESYLATE amlodipine besylate TABLET;ORAL 206367-003 Dec 10, 2015 AB RX No No   See Pricing   See Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Johnson and Johnson
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.